1. Department of Radiotherapy, Fengcheng Hospital of Fengxian District, Shanghai 201411, China.
2. Department of Oncological Surgery, Minhang Branch of Fudan University Shanghai Cancer Center, Shanghai 200240, China.
3. Department of General Surgery, Naval Medical Center of PLA, Shanghai 200052, China.
4. Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai Fengxian District Central Hospital, Shanghai 201499, China.
5. Department of Hematology, Anhui University of Science and Technology Affiliated Fengxian Hospital, Shanghai 201499, China.
#These authors contributed equally to this work as first authors.
Background: Multidrug resistance gene 1 (MDR-1) encodes for P-glycoprotein (P-gp) recognized for removing cytostatic drugs from tumor cells. MDR1 gene polymorphisms change function of P-gp. In this study, we are interested in investigating whether MDR1 C1236T single nucleotide polymorphisms (SNPs) affect the susceptibility and treatment-related toxicities in B-cell non-Hodgkin lymphoma (B-NHL) in the population of eastern China.
Materials and methods: A group of 107 B-NHL patients and 150 healthy donors, unrelated ethnic Han Chinese and residents of eastern China, were included in this study. The MDR1 C1236T polymorphisms were determined using polymerase chain reaction-allele specific primers after extraction of genomic DNA. Analyses were performed using SPSS and Arlequin software.
Results: MDR1 C1236T polymorphisms were not significantly related to the risk and treatment-related toxicities of B-NHL. A significant association between extranodal sites and C1236T allele was observed (C vs T: P=0.01).
Conclusion: Our findings could expand our understanding of MDR1 in B-NHL and provide references for further research in multidrug resistance.
Keywords: B-cell non-Hodgkin lymphoma, multidrug resistance 1 (MDR1), polymorphism, treatment-related toxicities